Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

Tomohiro Kaku; Takenori Hitaka; Akio Ojida; Nobuyuki Matsunaga; Mari Adachi; Toshimasa Tanaka; Takahito Hara; Masuo Yamaoka; Masami Kusaka; Teruaki Okuda; Satoru Asahi; Shuichi Furuya; Akihiro Tasaka

doi:10.1016/j.bmc.2011.08.066

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

Tomohiro Kaku, Takenori Hitaka, Akio Ojida, Nobuyuki Matsunaga, Mari Adachi, Toshimasa Tanaka, Takahito Hara, Masuo Yamaoka, Masami Kusaka, Teruaki Okuda, Satoru Asahi, Shuichi Furuya, Akihiro Tasaka

Research output: Contribution to journal › Article › peer-review

117 Citations (Scopus)

Abstract

A novel naphthylmethylimidazole derivative 1 and its related compounds were identified as 17, 20-lyase inhibitors. Based on the structure-activity relationship around the naphthalene scaffold and the results of a docking study of la in the homology model of 17, 20-1yase, the 6, 7-dihydro-5H-pyrrolo[l, 2-c]imidazole derivative (+)-3c was synthesized and identified as a potent and highly selective 17, 20-lyase inhibitor. Biological evaluation of (+)-3c at a dose of 1 mg/kg in a male monkey model revealed marked reductions in both serum testosterone and dehydroepiandrosterone concentrations. Therefore, (+)-3c (termed orteronel [TAK-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.

Original language	English
Pages (from-to)	6383-6399
Number of pages	17
Journal	Bioorganic and Medicinal Chemistry
Volume	19
Issue number	21
DOIs	https://doi.org/10.1016/j.bmc.2011.08.066
Publication status	Published - Nov 1 2011
Externally published	Yes

Keywords

17,20-Lyase
Orteronel
Prostate cancer
TAK-700

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Pharmaceutical Science
Drug Discovery
Clinical Biochemistry
Organic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bmc.2011.08.066

Cite this

Kaku, T., Hitaka, T., Ojida, A., Matsunaga, N., Adachi, M., Tanaka, T., Hara, T., Yamaoka, M., Kusaka, M., Okuda, T., Asahi, S., Furuya, S., & Tasaka, A. (2011). Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorganic and Medicinal Chemistry, 19(21), 6383-6399. https://doi.org/10.1016/j.bmc.2011.08.066

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. / Kaku, Tomohiro; Hitaka, Takenori; Ojida, Akio et al.
In: Bioorganic and Medicinal Chemistry, Vol. 19, No. 21, 01.11.2011, p. 6383-6399.

Research output: Contribution to journal › Article › peer-review

Kaku, T, Hitaka, T, Ojida, A, Matsunaga, N, Adachi, M, Tanaka, T, Hara, T, Yamaoka, M, Kusaka, M, Okuda, T, Asahi, S, Furuya, S & Tasaka, A 2011, 'Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer', Bioorganic and Medicinal Chemistry, vol. 19, no. 21, pp. 6383-6399. https://doi.org/10.1016/j.bmc.2011.08.066

@article{46c7d92e5583463ab081f54da683e2f5,

title = "Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer",

abstract = "A novel naphthylmethylimidazole derivative 1 and its related compounds were identified as 17, 20-lyase inhibitors. Based on the structure-activity relationship around the naphthalene scaffold and the results of a docking study of la in the homology model of 17, 20-1yase, the 6, 7-dihydro-5H-pyrrolo[l, 2-c]imidazole derivative (+)-3c was synthesized and identified as a potent and highly selective 17, 20-lyase inhibitor. Biological evaluation of (+)-3c at a dose of 1 mg/kg in a male monkey model revealed marked reductions in both serum testosterone and dehydroepiandrosterone concentrations. Therefore, (+)-3c (termed orteronel [TAK-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.",

keywords = "17,20-Lyase, Orteronel, Prostate cancer, TAK-700",

author = "Tomohiro Kaku and Takenori Hitaka and Akio Ojida and Nobuyuki Matsunaga and Mari Adachi and Toshimasa Tanaka and Takahito Hara and Masuo Yamaoka and Masami Kusaka and Teruaki Okuda and Satoru Asahi and Shuichi Furuya and Akihiro Tasaka",

year = "2011",

month = nov,

day = "1",

doi = "10.1016/j.bmc.2011.08.066",

language = "English",

volume = "19",

pages = "6383--6399",

journal = "Bioorganic and Medicinal Chemistry",

issn = "0968-0896",

publisher = "Elsevier Limited",

number = "21",

}

TY - JOUR

T1 - Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

AU - Kaku, Tomohiro

AU - Hitaka, Takenori

AU - Ojida, Akio

AU - Matsunaga, Nobuyuki

AU - Adachi, Mari

AU - Tanaka, Toshimasa

AU - Hara, Takahito

AU - Yamaoka, Masuo

AU - Kusaka, Masami

AU - Okuda, Teruaki

AU - Asahi, Satoru

AU - Furuya, Shuichi

AU - Tasaka, Akihiro

PY - 2011/11/1

Y1 - 2011/11/1

N2 - A novel naphthylmethylimidazole derivative 1 and its related compounds were identified as 17, 20-lyase inhibitors. Based on the structure-activity relationship around the naphthalene scaffold and the results of a docking study of la in the homology model of 17, 20-1yase, the 6, 7-dihydro-5H-pyrrolo[l, 2-c]imidazole derivative (+)-3c was synthesized and identified as a potent and highly selective 17, 20-lyase inhibitor. Biological evaluation of (+)-3c at a dose of 1 mg/kg in a male monkey model revealed marked reductions in both serum testosterone and dehydroepiandrosterone concentrations. Therefore, (+)-3c (termed orteronel [TAK-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.

AB - A novel naphthylmethylimidazole derivative 1 and its related compounds were identified as 17, 20-lyase inhibitors. Based on the structure-activity relationship around the naphthalene scaffold and the results of a docking study of la in the homology model of 17, 20-1yase, the 6, 7-dihydro-5H-pyrrolo[l, 2-c]imidazole derivative (+)-3c was synthesized and identified as a potent and highly selective 17, 20-lyase inhibitor. Biological evaluation of (+)-3c at a dose of 1 mg/kg in a male monkey model revealed marked reductions in both serum testosterone and dehydroepiandrosterone concentrations. Therefore, (+)-3c (termed orteronel [TAK-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.

KW - 17,20-Lyase

KW - Orteronel

KW - Prostate cancer

KW - TAK-700

UR - http://www.scopus.com/inward/record.url?scp=84856780403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856780403&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2011.08.066

DO - 10.1016/j.bmc.2011.08.066

M3 - Article

C2 - 21978946

AN - SCOPUS:84856780403

SN - 0968-0896

VL - 19

SP - 6383

EP - 6399

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

IS - 21

ER -

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this